Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis has to be proven to aid the probabilities of long-term survival for advanced lung cancer patients [2]. The gene discussed is PDCD1; the disease is lung carcinoma.